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CRF receptors are involved in the stress management of the cells and are believed to have a cytoprotective 
role in the body. CRF receptors have been reported to be potential drug targets for the treatment of 
neurodegenerative disorders. The cell line used in the study is ND7/23 (mouse neuroblastoma and rat 
dorsal root ganglion neuron hybridoma). The aim of the study was to confirm the expression of CRF 
receptors in ND7/23 cells and to determine if urocortin (Ucn) can enhance the expression of CRF 
receptors. ND7/23 cells were cultured in RPMI 1640 media and cells grown after the second passage 
were used for the experiments. RNA was extracted from the cells and amplified by RT-PCR to confirm 
the presence of CRF receptors. The cells were then subjected to oxidative stress by hydrogen peroxide 
(0.00375%) and divided into two groups i.e. control and Ucn (10-8 μM) treated. Later RNA was extracted 
from both group of cells and PCR was performed. Finally, densitometry analysis was conducted on the 
agarose gel to determine the quantity of PCR product formed. PCR experiment confirmed the expression 
of both CRF-R1 and CRF-R2 in the cell line, but CRF-R1 was found to be expressed more strongly. 
Densitometry analysis of the PCR product and calculation of the relative expression of CRF receptors 
indicated a higher level of expression of CRF receptors in samples treated with Ucn as compared to 
those that were kept untreated. The results indicate that Ucn may be useful for the management of neuro-
degenerative disorders and further studies may be carried out to establish its use as a therapeutic agent.
Uniterms: Urocortin. ND7/23 cells. Corticotrophin releasing factor. RT-PCR. Neuronal cells.
Receptores de CRF estão envolvidos na gestão do estresse das células e são acreditados para ter um 
papel de cito-proteção no organismo. Os receptores do CRF têm sido relatados como alvos potenciais 
de fármacos para o tratamento de doenças neurodegenerativas. A linhagem celular utilizada no estudo 
é ND7/23 (neuroblastoma de camundongo e hibridoma de raíz dorsal do neurônio ganglionar de 
rato). O objetivo do estudo foi confirmar o que a expressão de receptores de CRF em células ND7/23 
determinar se urocortina (Ucn) pode aumentar a expressão de receptores de CRF. Cultivaram-se células 
ND7/23 em meio RPMI 1640 e as células que cresceram após a segunda passagem foram usadas para 
os experimentos. O RNA foi extraído células e amplificado por RT-PCR para confirmar a presença de 
receptores de CRF. As células foram, então, submetidas a estresse oxidativo por peróxido de hidrogênio 
(0.00375 %) e divididas em dois grupos, ou seja, controle e tratadas com UCN (10-8 µM). Em seguida, 
o RNA foi extraído de ambos os grupo de células e realizou-se o PCR. Finalmente, realizou-se análise 
densitométrica em gel de agarose para determinar a quantidade de produto formado por PCR. O PCR 
confirmou a expressão de CRF-R1 e CRF-R2 na linhagem celular, mas o CRF-R1 expresso mais 
fortemente. A análise densitométrica do produto de PCR e o cálculo da expressão relativa de receptores 
de CRF indicaram um nível mais elevado de expressão de receptores de CRF em amostras tratadas com 
Ucn, em comparação com aqueles sem tratamento. Os resultados indicam que a Ucn pode ser útil no 
tratamento de doenças neurodegenerativas e mais estudos podem ser realizados para estabelecer seu 
uso como agente terapêutico.
Unitermos: Doenças neurodegenerativas/tratamento. Urocortina . Células ND7/23. RT-PCR. Células 
neuronais.
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INTRODUCTION
Corticotrophin releasing factor (CRF) was first 
discovered in 1981 and was found to be a regulator of 
the endocrine stress response (Bale, Wale, 2004). CRF 
receptors are members of G-protein coupled receptor 
(GPCR) family. The two main subtypes of CRF receptors 
are CRF receptor 1 (CRF-R1) and CRF receptor 2 
(CRF-R2), which are products of two separate genes 
(Roloff et al., 1998). These receptors have various splice 
variants that are expressed in both tissues of central 
and peripheral region, with CRF-R2 existing as α and 
β isoforms (Grigoriadis, 2001). Based on amino acid 
sequences, CRF-R1 and CRF-R2 have almost 70% 
homology, and only differ at one end of the amino acid 
sequence (Bale, Wale, 2004).
CRF is a vital regulator of endocrine response to 
stress (Meaney et al., 1996); it is found in the region of 
paraventricular nucleus (PVN) of the hypothalamus, central 
nucleus of amygdala and hindbrain regions of the CNS (Qiu 
et al., 2005). It is also found in peripheral regions, such as 
gut, skin and adrenal gland (Bale, Wale, 2004). CRF-R1 has 
been reported to be responsible for the stress response on the 
cellular level, whereas the role of CRF-R2 in stress response 
has not been clearly established yet (Qiu et al., 2005).
In the current study, the cell line used was ND7/23, 
which is a hybrid of mouse neuroblastoma (N18 tg 2) and 
rat dorsal root ganglion neuron, produced by PEG mediated 
cell fusion (Herold et al., 2009). ND7/23 cells had not been 
used for studies related to CRF receptors before. Therefore, 
there were no details available for the expression of CRF 
receptors in this cell line. The aim of this study was to detect 
if CRF receptors are expressed in ND7/23 cells.
Urocortin (Ucn) is a naturally occurring hormone, 
which has been identified as a natural analogue of CRF and 
a neuroprotective agent (Abuirmeileh et al., 2007). Ucn 
is a peptide comprising of 40 amino acids and it belongs 
to CRF peptide family, functioning via corticotrophin 
releasing factor receptors (CRFR) (Wang et al., 2008). 
Ucn has been found to have affinity for both CRFR1 and 
CRFR2 (Tezval et al., 2009). The possible cyto-protective 
role of Ucn has been suggested by many previous studies 
for cardiac myocytes (Brar et al., 2000). The optimum dose 
of Ucn to exert a protective effect for cardiac myocytes has 
been determined to be 10-8 M (Brar et al., 2002).
Mouse CRF-R1 protein has 97% homology with 
human CRF-R1 protein, whereas mouse CRF-R2 protein 
has 92% homology with human CRF-R2 protein. Mouse 
Ucn has around 79% similarity with human Ucn (Sequence 
homologies determined using NCBI/BLAST online). 
These observations were significant for the study since 
mouse cells were being used. High sequence homologies 
between mouse and human CRF-R1 and CRF-R2 protein 
and Ucn ensured that human CRF-R1 and CRF-R2 primers 
should provide appropriate PCR product. High sequence 
homologies also mean that the results can be applied to 
studies involving human models as well in the future 
(Kwitek et al., 2001).
Different neuro-degenerative disorders like 
Parkinson’s disease (PD) are caused due to the loss of 
neurons (Chinta et al., 2007). Originally, it was postulated 
that the cell death is caused by apoptosis, excitotoxic 
events or free radical production (Gandhi, Wood, 2005). 
More recently, it has been suggested that pre- and post-
natal neuroinflammation might be a cause of neuronal 
disorders (Block, Zecca, Hong, 2007). Therefore, 
protection of neuronal cells using Ucn can be extremely 
useful for untreatable neuronal disorders (Martin et al., 
2007). The latest efforts to treat such disorders have been 
focused on the neuronal level by protecting the neurons 
from apoptosis (Sredni et al., 2007). The main aim of the 
study was to explore more about the neuro-protective role 
of Ucn in cells subjected to oxidative stress by hydrogen 
peroxide. The results obtained from the current study can 
help establish the use of Ucn for the treatment of neuro-
degenerative disorders.
MATERIAL AND METHODS
Cell culture
The cell line used for the experiments was ND7/23 
rat dorsal root ganglia/mouse neuro-blastoma hybrid 
(acquired from ECACC). Frozen cells were thawed and 
then spun down in a centrifuge at 1500 rpm, supernatant 
was discarded and cells were re-suspended into RPMI-
1640 medium in 15 mL flasks. Flasks were then incubated 
for a few days in humidified incubator at 37 °C and 5% 
CO2 (Oliveira et al., 2010). For the second passage DPBS 
(Dulbecco’s phosphate buffered saline) was added to the 
flasks, cells were centrifuged and transferred to further 
flasks along with fresh RPMI 1640 media.
MTT assay
Toxicity of Ucn and hydrogen peroxide was 
determined using MTT assay, in order to identify the 
optimum therapeutic dose of Ucn and optimum sub-lethal 
dose of hydrogen peroxide for the experiments. To perform 
MTT assay 96 well plate format was used. 8 wells each, 
in four rows of the plate was filled with 100 µL of cell 
suspension containing ND7/23 cells suspended in RPMI-
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1640. The plate was left overnight in the incubator, to allow 
cells to grow. Next day the cells in the 96 wells plate were 
subjected to different concentrations of hydrogen peroxide, 
to induce oxidative stress and apoptosis. First well in each of 
the four rows was kept as control and then the next six wells 
were added with six different concentrations of hydrogen 
peroxide, which were 0.0018%, 0.00375%, 0.0075%, 
0.015%, 0.03% and 0.06%.
Another 96 well plate was also set up, where the 
wells were again filled with 100 µl of cell suspension and 
left over night in the incubator. In each of the first four 
rows of the plate, the first well was kept as control and 
cells in the next six wells were treated with increasing 
concentration of Ucn, which were 1×10-8 M, 2×10-8 M, 
4×10-8 M, 1×10-7 M, 2×10-7 M and 4×10-7 M.
RNA extraction
RNA extraction was carried out using the protocol 
mentioned by Chomczynski and Mackey (1995). Cultured 
cells from each flask were centrifuged, all cells were then 
homogenized with trizol and transferred to sterile Eppendorf 
tubes and centrifuged again. RNA pellet in the form of a 
faint smear appeared at the bottom of the tubes at the end 
of the process. The supernatant was removed carefully and 
1 mL of 75% ethanol was added to the tubes for desalting 
of the pellet and the samples were again centrifuged. 
Eppendorf concentrator (model 5301) was used to dry the 
RNA pellets. After drying the pellets, they were re-dissolved 
in 50 µL of diethylpyrocarbonate (DEPC) water.
Treatment of cells with hydrogen peroxide and 
Ucn
ND7/23 cells were cultured in four flasks and 
allowed to grow to adequate quantity. The cells in the first 
flask were used as control i.e. untreated (sample A). Cells 
in second flask were treated with 1×10-8 M Ucn (sample 
B). The third flask contained cells treated with 0.00375% 
(optimum sub-lethal concentration) hydrogen peroxide 
(sample C). In the fourth flask, cells were treated with both 
0.00375% (sub-lethal concentration) hydrogen peroxide 
and 1×10-8 M Ucn (sample D). After 24 hours of incubation 
of all the mentioned cell samples, RNA extraction was 
performed. 
PCR of RNA extracted from control and treated 
cell samples
The extracted RNA was subjected to PCR using rat 
CRFR primers. Since the extracted samples contained 
RNA, therefore, reverse transcriptase PCR (RT-PCR) was 
performed to identify expression of CRF receptors, for that 
purpose, Qiagen® one step PCR kit was used. 
RNA extracted from cell samples A, B, C and D 
were amplified by PCR and the same PCR protocol as 
mentioned earlier was utilized. First PCR was performed 
on sample A and B, where extracted RNA from both 
samples were mixed with each CRF-R1 primer, CRF-R2 
primer, GAPDH primer (housekeeping gene) and KIR 
6.1 primer (since Ucn is considered to function through 
potassium channel) in separate tubes and PCR was carried 
out. Second PCR was performed for samples treated 
with 0.00375% hydrogen peroxide with and without Ucn 
(sample C and D). Both samples were mixed separately 
with each primer i.e. CRF-R1, CRF-R2, GAPDH and KIR 
6.1 and PCR was performed.
The primer sequences of all the primers used to 
perform PCR are as follows.
Rat CRF-R1 primer:
Forward primer: 5’ ACAAACAATGGCTACCGGGA 3’
Reverse primer: 5’ TCATGGGGCCCTGGTAGAT 3’
Rat CRF-R2 primer:
Forward primer: 5’ TGTGGAAGGCTGCTACCTG 3’
Reverse primer: 5’ GTGTGCTTGATGCTGTGGAA 3’
GAPDH primer:
Forward primer: 5’ CATCATCTCTGCCCCCTCTG 3’
Reverse primer: 5’ CCTGCTTCACCACCTTCTTG 3’
KIR primer:
Forward primer: 5’ GCTTTGTGTCCATTGTGACTG 3’
Reverse primer: 5’ GCTGTCATGATTCCGATGTG 3’
Gel electrophoresis
2% agarose gel was prepared by dissolving 2 g 
agarose in 100 mL TBE buffer. Gel electrophoresis was 
performed using savant PS250 power pack for 60 minutes 
at 105 V. The PCR products from control and treated cell 
samples were also run on an agarose gel and visualized 
in UVipro light box visualizer; using UVtec gel analysis 
software (Figures III and IV).
Densitometric analysis
After all the PCRs were performed and products run 
on gel, gel densitometric analysis was performed to analyze 
the band size using UVtec gel analysis software. The same 
method as used by Pachner and Ricalton (1992) was utilized 
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for densitometric analysis. The band sizes provided an 
approximate idea of the amount of PCR product formed. 
The amount of product formed gave an estimate of the 
extent of receptor expression (Tables I and II).
CRF receptor expression
For the determination of relative expression of 
CRF receptors to GAPDH gene, the ratio of band areas 
(determined by densitometry) of GAPDH gene (PCR 
product) to CRF receptor gene (PCR product) were 
calculated for respective cell samples (untreated and 
treated with Ucn).
RESULTS AND DISCUSSION
ND7/23 cells exhibited slow growth during the 
first passage, whereas growth was much better in later 
passages. Over all ND7/23 cells displayed very good 
growth in RPMI 1640 media within 3-4 days.
MTT assay performed on cells treated with Ucn was 
used to determine cell viability. Mean values of percentage 
cell survival for 4 wells of each concentration of Ucn and 
hydrogen peroxide have been plotted in Figure 1 and 2, 
respectively. The percentage cell survival of each sample 
was calculated relative to the absorbance of control well. 
The figure shows that maximum cell viability is observed 
when cells were treated with Ucn at 1×10-8 µM dose, 
which is in accordance with the concentration by Brat et 
al. (2000), in the case of cardiac myocytes. Hence, this 
dose was used for all proceeding experiments.
Second MTT assay was performed to determine 
sub-lethal dose of hydrogen peroxide that could be used to 
induce oxidative stress to cells without causing complete 
cell death. 0.00375% hydrogen peroxide was found to 
cause significant stress to the cells and was therefore was 
chosen for all proceeding experiments.
In Figure 3 clear bands are visible in lane 2 and 3 that 
contain PCR products of control and GAPDH primer, but 
the band in lane 3 appears to be brighter than the band in 
lane 2. Lane 3 contained the PCR product of RNA sample 
from cells treated with Ucn. Clear bands are visible in lane 
4 and 5, which contained PCR product of CRF-R1 primer 
and controls; here as well the PCR product of RNA sample 
extracted from cells treated with Ucn is brighter than the 
FIGURE 1 – Effect of different concentrations of Ucn on ND7/23 
cells survival.
FIGURE 2 – Effect of different concentrations of hydrogen 
peroxide on ND7/23 cells survival.
FIGURE 3 - Agarose gel photograph showing PCR product of 
Controls with GAPDH primer, CRF-R1 primer, CRF-R2 primer 
and KIR 6.1 primer.
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with the band area produced by the housekeeping gene, 
which was GAPDH. Relative expression of CRF receptor 
to GAPDH was calculated using the values obtained by 
densitometry. Calculation of relative expression (Table III) 
of the CRF receptors to GAPDH products clearly indicates 
a higher level of expressions of CRF-R1 and CRF-R2 in 
samples treated with Ucn as compared to those, which 
were not treated with Ucn.
The current study has established the presence and 
expression of both CRF receptors in ND7/23 cell line, but 
the results also clearly suggest that CRF-R1 is expressed in 
much greater quantity as compared to CRF-R2. It has been 
confirmed by previous studies that Ucn binds to CRF-R2 
(Bale, Wale, 2004), but unlike CRF-R1, its effect on cell 
survival when working via CRF-R2 has not yet been 
TABLE III - Relative expression of CRF receptors to GAPDH 
receptor in all cell samples
Sample Relative expression
A + CRFR1 primer (untreated) 1.07
B + CRFR1 primer (treated with Ucn) 1.10
C + CRFR1 primer (untreated) 0.00
D + CRFR1 primer (treated with Ucn) 0.0877
C + CRFR2 primer (untreated) 0.00
D + CRFR2 primer (treated with Ucn) 0.7
TABLE II - Showing band areas by densitometric analysis of 
Figure 4
BAND BAND AREA
Lane 2 649
lane 3 989
Lane 4 Too small to calculate
Lane 5 868
Lane 7 693
Note: band area is mentioned in arbitrary units
TABLE I – Showing band areas by densitometry analysis of 
Figure 3
BAND BAND AREA
Lane 2 654
Lane 4 701
Lane 3 804
Lane 5 889
Note: band area is mentioned in arbitrary units
one not treated with Ucn. No bands are visible in lanes 6 
to 9; therefore, it can believed that no PCR product was 
formed with CRF-R2 and KIR6.1 primers, which could 
have been due to non-homologous primers, improper 
reaction conditions or that the cells do not express the 
genes at all. Visually it is evident that samples treated with 
Ucn resulted in brighter bands.
In Figure 4 clear bands are visible in lane 2 and 3 that 
contained PCR products of GAPDH primer and controls. 
The band in lane 3 is considerably brighter than the band 
in lane 2. Lane 3 contained PCR product of RNA sample 
extracted from the cell sample treated with Ucn. Clear 
band is visible in lane 5 that contains PCR product of RNA 
sample from cells treated with Ucn and CRF-R1 primer. 
A faint band is visible in lane 4 which contained RNA 
extracted from the cell sample that was not treated with 
Ucn. Lane 6 and 7 contained PCR products with CRF-R2 
primers and a band is only visible in lane 7 that contained 
RNA sample extracted from cell sample treated with Ucn. 
No bands are visible in lane 8 and 9 that contained PCR 
products with KIR6.1 primer, which could have been due 
to reasons as discussed earlier.
Densitometry analysis (Table I and II) was performed 
to determine the band area of PCR product obtained on 
the gel. The band area of CRFR primers was compared 
FIGURE 4 - Agarose gel photograph showing PCR products of 
samples treated with 0.00375% H2O2 with GAPDH, CRF-R1 
primer, CRF-R2 primer and KIR 6.1 primer.
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established (Sawada, Fukui, Hawkes, 2008). Therefore, 
greater expression of CRF-R1 certainly increase the 
chance of attaining more cell viability after treatment, but 
further experiments need to be conducted to confirm this 
phenomenon. The first indication of higher expression 
of CRF receptors in both figures was the brightness of 
the bands obtained from PCR products of all samples 
pre-treated with Ucn and the later calculations confirmed 
the hypothesis. Since it is known that Ucn binds to CRF 
receptors, and all other components in each sample treated 
with Ucn were same as in samples not treated with Ucn; 
thus the presence of higher amount of CRF receptor 
protein in the cell samples indicates that Ucn has up-
regulated the CRF gene. The increased amount of CRF 
receptor protein in samples could be either because of an 
increased expression or the presence of higher number 
of viable cells. The PCR product of GAPDH gene from 
cell sample treated with Ucn is brighter as compared to 
untreated sample, which could have been due to increased 
survival of cells in samples treated with Ucn.
Gene expression experiment was performed as a 
unique experiment due to lack of funds and for future 
studies it would be more useful if the experiment could 
be replicated to further confirm the results.
CONCLUSION
The results obtained from PCR confirmed that 
ND7/23 cells express CRF-R1 and CRF-R2. CRF-R1 
was found to be expressed more strongly as compared to 
CRF-R2. The results obtained from experiments showing 
increased concentration of RNA in samples treated with 
Ucn are suggestive that treatment of cells with Ucn has 
positive effect on CRF receptor expression. Amongst the 
PCR products, higher expression of CRF receptors was 
observed in samples that were treated with Ucn. From the 
set of experiments performed in this study there is evidence 
to suggest that Ucn has up regulated CRF receptors. Since 
CRF receptors are involved in the stress management of 
cells in the body, therefore increased expression of CRFR 
should increase the survival of cells by protecting against 
oxidative stress. The results obtained would be helpful 
in determining the use of Ucn for the treatment of neuro-
degenerative disorders like PD.
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